Transient Receptor Potential Channel 1 Potentially Serves As a Biomarker Indicating T/TNM Stages and Predicting Long-Term Prognosis in Patients With Renal Cell Carcinoma

Overview

Journal Front Surg

Specialty General Surgery

Date 2022 May 13

PMID 35548183

Authors

Liang Chen

Guang Shan

Minghuan Ge

Huijun Qian

Yue Xia

Affiliations

Soon will be listed here.

Abstract

Background: Transient receptor potential channel 1 (TRPC1) regulates the progression of several cancers, but its clinical implication in renal cell carcinoma (RCC) has not been explored yet. This study aimed to investigate the correlation of TRPC1 with clinical characteristics and prognosis in patients with RCC.

Methods: Totally, 177 patients with primary RCC who received surgical resection were retrospectively screened. Their tumor and paired adjacent tissue specimens were retrieved to assess TRPC1 mRNA expression using RT-qPCR and TRPC1 protein expression using immunohistochemistry (IHC).

Results: Both TRPC1 IHC score and TRPC1 mRNA expression were elevated in RCC tissue than in adjacent tissue (both < 0.001). Meanwhile, both TRPC1 IHC score and TRPC1 mRNA expression in tumor were associated with higher T stage (both = 0.02) and TNM stage ( = 0.009, = 0.003, respectively). However, no correlation was found in tumor TRPC1 IHC score or TRPC1 mRNA expression with other tumor properties (all > 0.05). Besides, the 3-, 5-, and 7-year overall survival (OS) were 81.4, 68.6, and 60.2%, respectively in patients with high tumor TRPC1 protein, while they were 89.3, 82.7, and 76.7%, respectively in patients with low tumor TRPC1 protein. High (vs. low) TRPC1 protein in the tumor was associated with shorter OS ( = 0.017), while high (vs. low) TRPC1 mRNA in the tumor was not correlated with OS ( = 0.144). By the forward stepwise method, TRPC1 protein expression independently predicted poor OS ( = 0.01, hazard ratio = 2.052).

Conclusion: TRPC1 serves as a potential biomarker reflecting tumor features and long-term survival profile in patients with RCC.

Citing Articles

SKF96365 Inhibits Tumor Proliferation by Inducing Apoptosis and Autophagy in Human Esophageal Squamous Cell Carcinoma.

Zhang J, Han H, Liu Y, Xu J, Zhang D, Wang W Int J Genomics. 2024; 2024:4501154.

PMID: 39165489 PMC: 11335422. DOI: 10.1155/2024/4501154.

TRPC Channels in the Physiology and Pathophysiology of the Renal Tubular System: What Do We Know?.

Englisch C, Paulsen F, Tschernig T Int J Mol Sci. 2023; 24(1).

PMID: 36613622 PMC: 9820145. DOI: 10.3390/ijms24010181.

The TRPC1 Channel Forms a PI3K/CaM Complex and Regulates Pancreatic Ductal Adenocarcinoma Cell Proliferation in a Ca-Independent Manner.

Schnipper J, Kouba S, Hague F, Girault A, Rybarczyk P, Telliez M Int J Mol Sci. 2022; 23(14).

PMID: 35887266 PMC: 9323718. DOI: 10.3390/ijms23147923.

References

Zhang Y, Lun X, Guo W . Expression of TRPC1 and SBEM protein in breast cancer tissue and its relationship with clinicopathological features and prognosis of patients. Oncol Lett. 2020; 20(6):392. PMC: 7656111. DOI: 10.3892/ol.2020.12255. View

Elzamzamy O, Penner R, Hazlehurst L . The Role of TRPC1 in Modulating Cancer Progression. Cells. 2020; 9(2). PMC: 7072717. DOI: 10.3390/cells9020388. View

Wiechno P, Kucharz J, Sadowska M, Michalski W, Sikora-Kupis B, Jonska-Gmyrek J . Contemporary treatment of metastatic renal cell carcinoma. Med Oncol. 2018; 35(12):156. DOI: 10.1007/s12032-018-1217-1. View

Capitanio U, Bensalah K, Bex A, Boorjian S, Bray F, Coleman J . Epidemiology of Renal Cell Carcinoma. Eur Urol. 2018; 75(1):74-84. PMC: 8397918. DOI: 10.1016/j.eururo.2018.08.036. View

Zhang L, Zhang Y, Zeng Y, Zhu J, Chen H, Wei X . TRPC1 inhibits the proliferation and migration of estrogen receptor-positive Breast cancer and gives a better prognosis by inhibiting the PI3K/AKT pathway. Breast Cancer Res Treat. 2020; 182(1):21-33. DOI: 10.1007/s10549-020-05673-8. View

Sun Y, Ye C, Tian W, Ye W, Gao Y, Feng Y . TRPC1 promotes the genesis and progression of colorectal cancer via activating CaM-mediated PI3K/AKT signaling axis. Oncogenesis. 2021; 10(10):67. PMC: 8511127. DOI: 10.1038/s41389-021-00356-5. View

Petejova N, Martinek A . Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015; 160(2):183-94. DOI: 10.5507/bp.2015.050. View

Ke C, Long S . Dysregulated transient receptor potential channel 1 expression and its correlation with clinical features and survival profile in surgical non-small-cell lung cancer patients. J Clin Lab Anal. 2022; 36(3):e24229. PMC: 8906054. DOI: 10.1002/jcla.24229. View

Reed Dunnick N . Renal cell carcinoma: staging and surveillance. Abdom Radiol (NY). 2016; 41(6):1079-85. DOI: 10.1007/s00261-016-0692-0. View

10.

Eccher A, Girolami I, Motter J, Marletta S, Gambaro G, Momo R . Donor-transmitted cancer in kidney transplant recipients: a systematic review. J Nephrol. 2020; 33(6):1321-1332. PMC: 7701067. DOI: 10.1007/s40620-020-00775-4. View

11.

Le Saux O, Freyer G, Negrier S . First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review. Clin Drug Investig. 2016; 36(5):389-99. DOI: 10.1007/s40261-016-0384-0. View

12.

Gray R, Harris G . Renal Cell Carcinoma: Diagnosis and Management. Am Fam Physician. 2019; 99(3):179-184. View

13.

Irnaten M, OMalley G, Clark A, OBrien C . Transient receptor potential channels TRPC1/TRPC6 regulate lamina cribrosa cell extracellular matrix gene transcription and proliferation. Exp Eye Res. 2020; 193:107980. DOI: 10.1016/j.exer.2020.107980. View

14.

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

15.

Padala S, Barsouk A, Thandra K, Saginala K, Mohammed A, Vakiti A . Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020; 11(3):79-87. PMC: 7239575. DOI: 10.14740/wjon1279. View

16.

He F, Peng F, Xia X, Zhao C, Luo Q, Guan W . MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. Diabetologia. 2014; 57(8):1726-36. DOI: 10.1007/s00125-014-3282-0. View

17.

Zeng Y, Zhang Y, Chen J, Zhang L, Gao W, Lin X . TRPC1 Inhibits Cell Proliferation/Invasion and Is Predictive of a Better Prognosis of Esophageal Squamous Cell Carcinoma. Front Oncol. 2021; 11:627713. PMC: 8039442. DOI: 10.3389/fonc.2021.627713. View

18.

Dhennin-Duthille I, Gautier M, Faouzi M, Guilbert A, Brevet M, Vaudry D . High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. Cell Physiol Biochem. 2011; 28(5):813-22. DOI: 10.1159/000335795. View

19.

Hegemann M, Kroeger N, Stenzl A, Bedke J . Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma. World J Urol. 2018; 36(6):849-854. DOI: 10.1007/s00345-018-2215-9. View